Revumenib citrate is under clinical development by Syndax Pharmaceuticals and currently in Pre-Registration for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). According to GlobalData, Pre-Registration drugs for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Revumenib citrate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Revumenib citrate overview

Revumenib citrate (SNDX-5613) is under development for the treatment of genetically-defined subset of acute leukemias with chromosomal rearrangements in the MLL gene such as relapsed and refractory acute lymphoblastic leukemia, relapsed and refractory acute myelobalstic leukemia and unresectable metastatic microsatellite stable colorectal cancer. It is administered through oral route in the form of capsules. The drug candidate acts by targeting interaction of menin with the mixed lineage leukemia (MLL) protein.

Syndax Pharmaceuticals overview

Syndax Pharmaceuticals (Syndax) is a biopharmaceutical company that discovers, develops and commercializes therapies for multiple cancer indications. The company’s product portfolio includes SNDX-5613, a novel orally menin-MLL1 inhibitor used for the treatment of MLLr or mNPM1 acute leukemias; and SNDX-6352 (Axatilimab), a colony stimulating factor 1 receptor (CSF-1R) to treat chronic graft versus host disease (cGVHD). It is also evaluating entinostat (SNDX-275), a class I HDAC inhibitor against multiple solid tumors. Syndax product candidate are also used for the treatment of non-small cell lung cancer and melanoma, ovarian cancer and other indications. Syndax is headquartered in Waltham, Massachusetts, the US.

For a complete picture of Revumenib citrate’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.